How much is medical innovation that shortens a pandemic shutdown worth?
Core argument: Medical innovation that shortens the US pandemic shutdown by a single workday is valued at roughly $30bn, rising to $590bn for a one-month reduction and nearly $2tn for a quarter.
Medical innovation that could shorten the US shutdown by one workday is valued at ~$30bn, highlighting the significant economic impact of accelerating the end of pandemic restrictions. If innovations in medicine, testing, manufacturing, or workplace mitigation could reduce the shutdown by a month, their value would rise to $590bn, and by a quarter, nearly $2tn. The cumulative costs of the shutdown as of April 26, 2020, reached $8,096 per household, totaling $1tn. These costs include mortality costs (24% of total) and market and nonmarket costs of economic inactivity. The analysis underscores the immense economic benefits of medical innovation in restoring normal economic activity, despite regulatory challenges.


